Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
CD19+CD24hiCD38hi B Cells Exhibit Regulatory Capacity in Healthy Individuals but Are Functionally Impaired in Systemic Lupus Erythematosus Patients
20101.2k citationsFabian Flores‐Borja, David Isenberg et al.profile →
Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNFα Therapy
20041.0k citationsMichael R. Ehrenstein, David Isenberg et al.profile →
Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
2009972 citationsCaroline Gordon, David Isenberg et al.profile →
Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
2009734 citationsDavid Isenberg, David Jayne et al.profile →
The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index in patients with Systemic Lupus Erythematosus
1997587 citationsPaul R. Fortin, Caroline Gordon et al.profile →
CD19 + CD24 hi CD38 hi B Cells Maintain Regulatory T Cells While Limiting T H 1 and T H 17 Differentiation
2013539 citationsFabian Flores‐Borja, Anneleen Bosma et al.Science Translational Medicineprofile →
Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis
2011421 citationsDavid Jayne, David Isenberg et al.profile →
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial
Countries citing papers authored by David Isenberg
Since
Specialization
Citations
This map shows the geographic impact of David Isenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Isenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Isenberg more than expected).
This network shows the impact of papers produced by David Isenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Isenberg. The network helps show where David Isenberg may publish in the future.
Co-authorship network of co-authors of David Isenberg
This figure shows the co-authorship network connecting the top 25 collaborators of David Isenberg.
A scholar is included among the top collaborators of David Isenberg based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with David Isenberg. David Isenberg is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Ciurtin, Coziana & David Isenberg. (2016). Biologics in rheumatology: New developments, clinical uses and health implication. UCL Discovery (University College London).1 indexed citations
5.
Isenberg, David, Anisur Rahman, David Jayne, et al.. (2014). Response to Rituximab in Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register. UCL Discovery (University College London).1 indexed citations
6.
Flores‐Borja, Fabian, Anneleen Bosma, Dorothy Hui Lin Ng, et al.. (2013). CD19 + CD24 hi CD38 hi B Cells Maintain Regulatory T Cells While Limiting T H 1 and T H 17 Differentiation. Science Translational Medicine. 5(173). 173ra23–173ra23.539 indexed citations breakdown →
Gordon, P., Fowzia Ibrahim, Anna Kowalczyk, et al.. (2011). One Year Randomised Controlled Trial of SEcond Line Agents in Myositis (SELAM): Late Additional immunosuppression is Ineffective in Patients Who Have Partially Responded to Steroids. UCL Discovery (University College London).2 indexed citations
9.
Wofsy, David, et al.. (2010). Nonrenal Disease Activity Following Mycophenolate Mofetil or Intravenous Cyclophosphamide as Induction Treatment for Lupus Nephritis. UCL Discovery (University College London).1 indexed citations
10.
Allen, Elizabeth, Patrick Kiely, RG Cooper, et al.. (2005). Inter-rater reliability and validity of two disease activity assessment tools in patients with idiopathic inflammatory myositis (IIM). UCL Discovery (University College London).1 indexed citations
11.
Chinoy, Hector, Fiona Salway, Noreen Fertig, et al.. (2005). The UK Adult Onset Myositis Immunogenetic Collaboration (AOMIC): In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype rather than by myositis sub type.. UCL Discovery (University College London).2 indexed citations
12.
Isenberg, David, et al.. (2004). Oxford textbook of rheumatology. UCL Discovery (University College London).
13.
Ehrenstein, Michael R., et al.. (2004). DEFECTS IN THE GENERATION AND FUNCTION OF REGULATORY T CELLS IN RHEUMATOID ARTHRITIS: REVERSAL BY ANTI-TNF alpha THERAPY. UCL Discovery (University College London).1 indexed citations
14.
Cambridge, Geraldine, et al.. (2004). B lymphocyte depletion in the treatment of systemic lupus erythematosus.. UCL Discovery (University College London).10 indexed citations
15.
Ehrenstein, Michael R., et al.. (2003). TREATMENT OF REFRACTORY LUPUS NEPHRITIS WITH B LYMPHOCYTE DEPLETION. UCL Discovery (University College London).8 indexed citations
16.
Papadaki, Lucienne, et al.. (1997). Genetic structural and functional properties of a human IgG anti-DNA autoantibody. UCL Discovery (University College London).1 indexed citations
17.
Mackie, IJ, et al.. (1995). THE USE OF ANTI-BETA-2GPI ASSAY FOR DISCRIMINATION BETWEEN ANTICARDIOLIPIN ANTIBODIES ASSOCIATED WITH INFECTION AND INCREASED RISK OF THROMBOSIS. UCL Discovery (University College London).1 indexed citations
18.
Alavi, Azita, et al.. (1990). The significance of changes in IgG carbohydrate in rheumatoid arthritis and tuberculosis.. UCL Discovery (University College London).
19.
Mackenzie, Lorna, et al.. (1988). GALACTOSE RESIDUES IN CHRONIC INFLAMMATORY DISEASE - REPLY. UCL Discovery (University College London).1 indexed citations
20.
Edwards, R. H. T., David Isenberg, C. M. Wiles, A. Young, & M L Snaith. (1981). The Investigation of Inflammatory Myopathy. Journal of the Royal College of Physicians of London. 15(1). 19–23.12 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.